AR-Variant–Positive CTC: A Surrogate for a Surrogate for Taxane Therapy Outcome?
Abstract
Circulating tumor cells' (CTC) biomarkers may become indicators for selection of therapy. The presence of androgen receptor (AR)-variant–positive CTCs may be markers indicating the need for switching therapy. Methods for AR-variant mRNA isolation from CTCs and confirmation of expression are critical factors needed for these techniques to be clinically applicable.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Mar 15, 2019
- Source ID
- 10.1158/1078-0432.ccr-18-3727
Entities
People
- Bruce Montgomery
- Scott M Dehm
- Stephen R Plymate
Organizations
- National Cancer Institute
- Prostate Cancer Foundation
- University of Minnesota
- University of Washington